Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

被引：0
|
作者：
Kalinsky, Kevin [1 ]
Bianchini, Giampaolo [2 ]
Hamilton, Erika P. [3 ]
Graff, Stephanie L. [4 ]
Park, Kyong Hwa [5 ]
Jeselsohn, Rinath [6 ]
Demirci, Umut [7 ]
Martin, Miguel [8 ,9 ]
Layman, Rachel M. [10 ]
Hurvitz, Sara A. [11 ,12 ]
Sammons, Sarah L. [6 ]
Kaufman, Peter A. [13 ]
Munoz, Montserrat [9 ,14 ]
Tseng, Ling-Ming [15 ]
Knoderer, Holly [16 ]
Nguyen, Bastien [16 ]
Zhou, Yanhong [16 ]
Ravenberg, Elizabeth [16 ]
Litchfield, Lacey M. [16 ]
Wander, Seth Andrew [17 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[2] IRCCS Osped San Raffaele, Milan, Italy
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA
[5] Korea Univ, Anam Hosp, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea
[6] Dana Farber Canc Inst, Boston, MA USA
[7] Uskudar Univ, Fac Med, Mem Ankara Hosp, Med Oncol, Ankara, Turkiye
[8] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[9] GEICAM Spanish Breast Canc Grp, Madrid, Spain
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[11] Univ Washington, Sch Med, Seattle, WA USA
[12] Fred Hutchinson Canc Ctr, Seattle, WA USA
[13] Univ Vermont, Canc Ctr, Burlington, VT 05405 USA
[14] Hosp Clin Barcelona, Barcelona, Spain
[15] Taipei Vet Gen Hosp, Taipei, Taiwan
[16] Eli Lilly & Co, Indianapolis, IN USA
[17] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.17_suppl.LBA1001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：LBA1001 / LBA1001
页数：1
相关论文
共 50 条
  • [41] Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2-metastatic breast cancer
    Mayer, Erica L.
    Wander, Seth A.
    Regan, Meredith M.
    DeMichele, Angela M.
    Forero, Andres
    Rimawi, Mothaffar F.
    Ma, Cynthia X.
    Cristofanilli, Massimo
    Anders, Carey K.
    Bartlett, Cynthia Huang
    Koehler, Maria
    Winer, Eric P.
    Burstein, Harold J.
    CANCER RESEARCH, 2018, 78 (04)
  • [42] Treatment postprogression in women with endocrine-resistant HR+/HER2-advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3
    Turner, N. C.
    Andre, F.
    Cristofanilli, M.
    Verma, S.
    Iwata, H.
    Loi, S.
    Harbeck, N.
    Ro, J.
    Colleoni, M.
    Zhan, K. G.
    Bartlett, C. Huang
    Giorgetti, C.
    Slamon, D.
    CANCER RESEARCH, 2017, 77
  • [43] Randomized phase II trial of venetoclax plus fulvestrant versus fulvestrant in estrogen receptor+, HER2-locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.
    Lindeman, Geoffrey J.
    Bardia, Aditya
    Bowen, Rebecca
    Flechais, Aulde
    Lei, Guiyuan
    Hogea, Alexandra
    Mobasher, Mehrdad
    Rafii, Saeed
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Dalpiciclib and chidamide in patients with HR+/HER2-advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial
    Wang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Dalpiciclib and tucidinostat in patients with HR+/HER2-advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial
    Wang, Tao
    Zhou, Jinmei
    Wu, Xuexue
    Jiang, Zefei
    CANCER RESEARCH, 2024, 84 (09)
  • [46] Therapy of HR+/HER2-advanced Breast Cancer CDK4/6 Inhibitors: Studies, Everyday Healthcare and Guidelines
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
  • [47] Baseline gene expression patterns of CDK4/6 inhibitor-naive or - refractory HR+, HER2-advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane
    Bardia, Aditya
    Modi, Shanu
    Cortes, Javier
    Campone, Mario
    Dirix, Luc
    Ma, Brigette
    Beck, J. Thaddeus
    Chaves, Jorge
    Weise, Amy
    Vuky, Jacqueline
    Lopes, Gilberto
    Gil-Gil, Miguel
    Liu, Xiaochun
    He, Wei
    Su, Faye
    Miller, Michelle
    Chavez-MacGregor, Mariana
    CANCER RESEARCH, 2018, 78 (13)
  • [48] Dalpiciclib versus placebo plus fulvestrant in HR+/HER2-advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
    Xu, Binghe
    Zhang, Qingyuan
    Zhang, Pin
    Hu, Xichun
    Li, Wei
    Tong, Zhongsheng
    Sun, Tao
    Teng, Yuee
    Wu, Xinhong
    Ouyang, Quchang
    Yan, Xi
    Cheng, Jing
    Liu, Qiang
    Feng, Jifeng
    Wang, Xiaojia
    Zhu, Xiaoyu
    Wu, Fei
    Zhang, Xiao
    Zou, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] CAPItello-292 Phase 3: An open-label, randomized study of capivasertib, fulvestrant, and investigator's choice of CDK4/6 inhibitor (palbociclib or ribociclib) in HR+/HER2-advanced breast cancer
    Rugo, Hope
    Pistilli, Barbara
    Collins, Julie
    D'Cruz, Celina
    Gresty, Christopher
    Sommavilla, Roberto
    Sudhan, Dhivya
    Miller, Claire
    Ha, Juyoung
    Neven, Patrick
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial
    Jerusalem, G.
    Delea, T.
    Martin Jimenez, M.
    De laurentiis, M.
    Nusch, A.
    Beck, J. T.
    Chan, A.
    Im, S-A.
    Neven, P.
    Lonshteyn, A.
    Chandiwana, D.
    Lanoue, B.
    Fasching, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S66 - S66
12345